Nguyen K Tram1, Ting-Heng Chou1, Laila N Ettefagh1, Kyra Deep1, Adam J Bobbey2, Anthony N Audino3, Mitchel R Stacy4,5,6. 1. Center for Regenerative Medicine, The Research Institute at Nationwide Children's Hospital, 575 Children's Crossroad, WB4131, Columbus, OH, 43215, USA. 2. Department of Radiology, Nationwide Children's Hospital, Columbus, OH, USA. 3. Division of Hematology/Oncology/BMT, Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA. 4. Center for Regenerative Medicine, The Research Institute at Nationwide Children's Hospital, 575 Children's Crossroad, WB4131, Columbus, OH, 43215, USA. Mitchel.Stacy@NationwideChildrens.org. 5. Division of Vascular Surgery and Diseases, Department of Surgery, The Ohio State University College of Medicine, Columbus, OH, USA. Mitchel.Stacy@NationwideChildrens.org. 6. Interdisciplinary Biophysics Graduate Program, The Ohio State University, Columbus, OH, USA. Mitchel.Stacy@NationwideChildrens.org.
Abstract
OBJECTIVES: The objective of this study was to use computed tomography (CT) imaging to quantify chemotherapy-induced changes in body composition (BC) in pediatric, adolescent, and young adult (AYA) patients with lymphoma and to compare image-derived changes in BC measures to changes in traditional body mass index (BMI) measures. METHODS: Skeletal muscle (SkM), subcutaneous adipose tissue (SAT), and visceral adipose tissue (VAT) volumes were manually segmented using low-dose CT images acquired from a 10-year retrospective, single-site cohort of 110 patients with lymphoma. CT images and BMI percentiles (BMI%) were acquired from baseline and first therapeutic follow-up. CT image segmentation was performed at vertebral level L3 using 5 consecutive axial CT images. RESULTS: CT imaging detected significant treatment-induced changes in BC measures from baseline to first follow-up time points, with SAT and VAT significantly increasing and SkM significantly decreasing. BMI% measures did not change from baseline to first follow-up and were not significantly correlated with changes in image-derived BC measures. Patients who were male, younger than 12 years old, diagnosed with non-Hodgkin's lymphoma, and presented with stage 3 or 4 disease gained more adipose tissue and lost more SkM in response to the first cycle of treatment compared to their clinical counterparts. CONCLUSIONS: Standard of care CT imaging can quantify treatment-induced changes in BC that are not reflected by traditional BMI assessment. Image-based monitoring of BC parameters may offer personalized approaches to lymphoma treatment for pediatric and AYA patients by guiding cancer treatment recommendations and subsequently enhance clinical outcomes. KEY POINTS: • Standard of care low-dose CT imaging quantifies chemotherapy-induced changes in body composition in pediatric, adolescent, and young adults with lymphoma. • Body mass index could not detect changes in body composition during treatment that were quantified by CT imaging. • Pediatric and AYA patients who were male, younger than 12 years old, and diagnosed with non-Hodgkin's lymphoma, and presented with stage 3 or 4 disease gained more adipose tissue and lost more skeletal muscle tissue in response to the first cycle of treatment compared to their clinical counterparts.
OBJECTIVES: The objective of this study was to use computed tomography (CT) imaging to quantify chemotherapy-induced changes in body composition (BC) in pediatric, adolescent, and young adult (AYA) patients with lymphoma and to compare image-derived changes in BC measures to changes in traditional body mass index (BMI) measures. METHODS: Skeletal muscle (SkM), subcutaneous adipose tissue (SAT), and visceral adipose tissue (VAT) volumes were manually segmented using low-dose CT images acquired from a 10-year retrospective, single-site cohort of 110 patients with lymphoma. CT images and BMI percentiles (BMI%) were acquired from baseline and first therapeutic follow-up. CT image segmentation was performed at vertebral level L3 using 5 consecutive axial CT images. RESULTS: CT imaging detected significant treatment-induced changes in BC measures from baseline to first follow-up time points, with SAT and VAT significantly increasing and SkM significantly decreasing. BMI% measures did not change from baseline to first follow-up and were not significantly correlated with changes in image-derived BC measures. Patients who were male, younger than 12 years old, diagnosed with non-Hodgkin's lymphoma, and presented with stage 3 or 4 disease gained more adipose tissue and lost more SkM in response to the first cycle of treatment compared to their clinical counterparts. CONCLUSIONS: Standard of care CT imaging can quantify treatment-induced changes in BC that are not reflected by traditional BMI assessment. Image-based monitoring of BC parameters may offer personalized approaches to lymphoma treatment for pediatric and AYA patients by guiding cancer treatment recommendations and subsequently enhance clinical outcomes. KEY POINTS: • Standard of care low-dose CT imaging quantifies chemotherapy-induced changes in body composition in pediatric, adolescent, and young adults with lymphoma. • Body mass index could not detect changes in body composition during treatment that were quantified by CT imaging. • Pediatric and AYA patients who were male, younger than 12 years old, and diagnosed with non-Hodgkin's lymphoma, and presented with stage 3 or 4 disease gained more adipose tissue and lost more skeletal muscle tissue in response to the first cycle of treatment compared to their clinical counterparts.
Authors: Bette J Caan; Elizabeth M Cespedes Feliciano; Carla M Prado; Stacey Alexeeff; Candyce H Kroenke; Patrick Bradshaw; Charles P Quesenberry; Erin K Weltzien; Adrienne L Castillo; Taiwo A Olobatuyi; Wendy Y Chen Journal: JAMA Oncol Date: 2018-06-01 Impact factor: 31.777
Authors: Carla M M Prado; Isac S F Lima; Vickie E Baracos; Robert R Bies; Linda J McCargar; Tony Reiman; John R Mackey; Michelle Kuzma; Vijaya L Damaraju; Michael B Sawyer Journal: Cancer Chemother Pharmacol Date: 2010-03-05 Impact factor: 3.333
Authors: Carla M M Prado; Yara L M Maia; Michael Ormsbee; Michael B Sawyer; Vickie E Baracos Journal: Anticancer Agents Med Chem Date: 2013-10 Impact factor: 2.505
Authors: Patrick A Thompson; Gary L Rosner; Katherine K Matthay; Theodore B Moore; Lisa R Bomgaars; Kenneth J Ellis; Jamie Renbarger; Stacey L Berg Journal: Cancer Chemother Pharmacol Date: 2008-11-20 Impact factor: 3.333
Authors: Carla M M Prado; Vickie E Baracos; Linda J McCargar; Marina Mourtzakis; Karen E Mulder; Tony Reiman; Charles A Butts; Andrew G Scarfe; Michael B Sawyer Journal: Clin Cancer Res Date: 2007-06-01 Impact factor: 12.531
Authors: Louise E Daly; Éadaoin B Ní Bhuachalla; Derek G Power; Samantha J Cushen; Karl James; Aoife M Ryan Journal: J Cachexia Sarcopenia Muscle Date: 2018-01-09 Impact factor: 12.910